Post-Marketing Surveillance of Perjeta in Breast Cancer
Post-Marketing Surveillance of Perjeta in Breast Cancer
This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 1000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in Korea. Participants who are administered with pertuzumab according to medical opinions of the doctor in charge of surveillance will be registered for this study and treated with pertuzumab under the approval conditions of the product in Korea.
Inclusion Criteria:
Exclusion Criteria:
Gyeongsangnam-do, 50612, South Korea
Jeollanam-do, 58128, South Korea
Jeonlabuk-do, 54538, South Korea
Seoul, 01812, South Korea